CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
Brian G. Till(University of Washington), Oliver W. Press(Fred Hutch Cancer Center), Michael C. Jensen(Seattle Children's Hospital), David G. Maloney(Fred Hutch Cancer Center), Philip D. Greenberg(University of Washington), Stephen J. Forman(City Of Hope National Medical Center), John M. Pagel(University of Washington), Yukang Lin(Fred Hutch Cancer Center), Andrew Raubitschek, Lihua E. Budde(City Of Hope National Medical Center), Stanley R. Riddell(Fred Hutch Cancer Center), Jinjuan Wang(Fred Hutch Cancer Center), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Xiaojun Qian(Wuxi No.2 People's Hospital), Catherine Lindgren(Unknown)
Cited by 530
Related Papers
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
|New England Journal of Medicine|1995|1.8k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k